Kamath Sangita D, Kumar Manish, Saha Sudip, Sunder Ashok
Department of General Medicine, Tata Main Hospital, Tata Steel, Jamshedpur, Jharkhand, India.
Indian J Pharmacol. 2025 May 1;57(3):193-195. doi: 10.4103/ijp.ijp_777_22. Epub 2025 Jul 9.
Eltrombopag is a thrombopoietin receptor agonist which is used an off-label treatment for thrombocytopenia in chronic liver disease (CLD). It is US Food and Drug Administration approved in the treatment of immune thrombocytopenia. However, the literature review suggests its use is associated with increased risk of venous thrombosis including portal vein thrombosis (PVT). There have been several case reports of developing PVT during treatment with Eltrombopag in patients with CLD of varying etiology. We report the case of nonalcohol steatohepatitis-associated CLD with concomitant immune thrombocytopenia who developed PVT 15 days after starting eltrombopag for thrombocytopenia. Our case suggests the possible causation of PVT by eltrombopag in patients with CLD and the need for caution and continuous vigilance for detection of such a complication.
艾曲泊帕是一种血小板生成素受体激动剂，被用于慢性肝病（CLD）血小板减少症的非标签治疗。它已获美国食品药品监督管理局批准用于治疗免疫性血小板减少症。然而，文献综述表明，其使用与静脉血栓形成风险增加有关，包括门静脉血栓形成（PVT）。在不同病因的CLD患者中，已有数例使用艾曲泊帕治疗期间发生PVT的病例报告。我们报告了一例非酒精性脂肪性肝炎相关的CLD合并免疫性血小板减少症患者，在开始使用艾曲泊帕治疗血小板减少症15天后发生了PVT。我们的病例提示，CLD患者中艾曲泊帕可能导致PVT，需要谨慎并持续警惕以检测此类并发症。
